Modulation of microbiota, inflammation, iron status and gene expression of affected receptors in Parkinson’s disease rat model by synbiotic and dark chocolate.

Publication date: Jul 04, 2025

Parkinson’s disease is among the neurodegenerative diseases that have no promising remedies. The present research is dealing with searching the associations between molecular, biochemical and microbiota changes in Parkinson’s disease rat model with and without intervention with dark chocolate as prebiotic or a mixture of probiotics (Lactobacillus plantarum EMCC 1039, Lactobacillus acidophilus and Bifidobacterium lactis BB12) during feeding a diet containing oat as prebiotic collectively designated as synbiotic (Sb). Four groups of rats were assigned; a normal control (C), a group given rotenone to induce Parkinson’s disease (P), and two test groups treated with rotenone; one received synbiotic (PSb) and the other treated by dark chocolate (PCh). Results showed plasma soluble transferrin receptor /log ferritin ratios that elevated in the P group denoting anemia was reduced in the test groups; with superiority to Sb. The increased brain malondialdehyde (MDA) together with the decreased glutathione (GSH) indicating high oxidative stress in the P group were improved in the test groups. Immune system that was affected in the P group by reduction of plasma CD4 which is the cluster of differentiation 4 and elevation of brain tumor necrosis factor-α (TNF-α) and plasma interferon γ (IFNγ) was improved in the test groups and completely amended concerning IFNγ; Sb showed more promising effect than chocolate concerning TNF-α and CD4. Up-regulation of the brain divalent metal transporter 1 gene (DMT1) in the P group was down-regulated significantly in the test groups till matching that of the C group. Down-regulation of brain dopamine receptor D1 (DRD1) gene expression was significantly up-regulated in the test groups with superiority of Sb. Brain histopathological changes in the P group were improved on treatment with either chocolate or Sb with more promising effect by Sb. The cecum content of Firmicutes (F) showed no difference among the different groups while Bacteroidetes (B) was significantly reduced on treatment with chocolate compared to all groups with significant increase of F/B. Cecum Lactobacilli showed significant increase in the PSb group compared to all other groups. It could be concluded that treatment with dark chocolate and Sb improved experimental PD with variable degrees.

Open Access PDF

Concepts Keywords
Bb12 Animals
Chocolate Brain
Neurodegenerative Cecum microbiota
Plasma Chocolate
Probiotics Dark chocolate
Disease Models, Animal
DMT1
DRD1
Gastrointestinal Microbiome
Inflammation
Inflammation
Iron
Iron
Iron status
Male
Microbiota
Oxidative Stress
Oxidative stress
Parkinson Disease
Parkinson’s disease
Rats
Rats
Receptors, Transferrin
Receptors, Transferrin
Synbiotic
Synbiotics

Semantics

Type Source Name
disease MESH inflammation
drug DRUGBANK Iron
disease MESH Parkinson’s disease
disease MESH neurodegenerative diseases
pathway REACTOME Neurodegenerative Diseases
drug DRUGBANK Lactobacillus plantarum
drug DRUGBANK Rotenone
disease MESH anemia
drug DRUGBANK Glutathione
disease MESH oxidative stress
pathway REACTOME Immune System
drug DRUGBANK Dopamine
disease MESH pathogenesis
drug DRUGBANK Coenzyme M
disease MESH dysbiosis
drug DRUGBANK Oxygen
disease MESH tremors
disease MESH death
disease MESH mitochondrial dysfunction
drug DRUGBANK Bean
disease MESH weight gain
disease MESH Parkinsonism
drug DRUGBANK Isoxaflutole
drug DRUGBANK Lactic Acid
disease MESH anxiety
pathway REACTOME Fatty acids
disease MESH brain inflammation
disease MESH atrophy
disease MESH neurofibrillary tangles
disease MESH demyelination
disease MESH hemorrhage
disease MESH gliosis
pathway REACTOME Apoptosis
disease MESH necrosis
disease MESH malnutrition
drug DRUGBANK Bifidobacterium longum infantis
disease MESH neuroinflammation
drug DRUGBANK Amino acids
disease MESH iron deficiency anemia
pathway REACTOME Hemostasis
pathway REACTOME Vitamins
disease MESH tryptophan
drug DRUGBANK L-Tryptophan
pathway REACTOME Intestinal absorption
drug DRUGBANK Hydrogen peroxide
pathway REACTOME Adaptive Immune System
drug DRUGBANK Theobromine
drug DRUGBANK Caffeine
drug DRUGBANK Phenethylamine
pathway REACTOME Release
drug DRUGBANK Norepinephrine
drug DRUGBANK L-Tyrosine
drug DRUGBANK Serotonin
disease MESH nerve degeneration
drug DRUGBANK Ethanol
drug DRUGBANK Water
drug DRUGBANK Quercetin
drug DRUGBANK Dimethyl sulfoxide
drug DRUGBANK Olive oil
drug DRUGBANK Pentobarbital
drug DRUGBANK Formaldehyde
pathway REACTOME Dopamine receptors
drug DRUGBANK Sunflower oil
drug DRUGBANK Microcrystalline cellulose
drug DRUGBANK Guanosine
drug DRUGBANK Carboxyamidotriazole
pathway KEGG Ferroptosis
disease MESH lifestyle
disease MESH alcoholic steatohepatitis
disease MESH obesity
disease MESH inflammatory bowel disease
pathway KEGG Inflammatory bowel disease
disease MESH rheumatoid arthritis
pathway KEGG Rheumatoid arthritis
disease MESH cardiovascular disease
disease MESH cancer
disease MESH Gastrointestinal disorders
pathway KEGG Parkinson disease
disease MESH iron deficiency
disease MESH infection
drug DRUGBANK Zinc
drug DRUGBANK Linoleic acid
disease MESH metabolic syndrome
pathway REACTOME Reproduction
disease MESH Disease Models Animal

Original Article

(Visited 2 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *